Abstract

RECENT ADVANCEMENTS IN THE MANAGEMENT OF TRIPLE NEGATIVE BREAST CANCER

*Gopinath S., Midhunasree P., Arthi S., Kowsalya R., Soundarya M. and Suruthisri U.

.

Abstract

Breast cancer is the most prevalent cancer diagnosed among women around the world, occurring with a lifetime risk of one in eight. In US it accounts for one third of all cancers in women and out of which 15%–20% of breast cancers accounts for triple-negative breast cancers (TNBCs). TNBC is much higher in Asians i.e. 25-30%. Triple negative breast cancer does not express estrogen receptor, progesterone receptor and human epidermal growth factor. Usually this type of cancers shows aggressive behavior, distant metastasis and poor prognosis when compared to hormonal positive breast cancer patients. Patients with early stage tripe negative breast cancer patients have better chemotherapy response rates than other type patients but more likely to get early relapse, visceral metastasis, and shorter survival. Due to lack of expression of ER, PR and HER2, triple negative breast cancer patients will have less therapeutic options unlike hormonal receptor positive patients whom were greatly benefited from drugs like tamoxifen and transtuzumab which increases the survival of the patients. This subject review will focus on existing therapies and recent advancements in the treatment of triple negative breast cancer patients.

Keywords: Triple Negative Breast Cancer, Luminal Cells, ER Negative And Positive.